Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations by Berghmans, Thierry et al.
GUIDELINES
Surrogate markers predicting overall
survival for lung cancer: ELCWP
recommendations
T. Berghmans, F. Pasleau, M. Paesmans, Y. Bonduelle, J. Cadranel, I. Cs Toth,
C. Garcia, V. Giner, S. Holbrechts, J.J. Lafitte, J. Lecomte, I. Louviaux, E. Markiewicz,
A.P. Meert, M. Richez, M. Roelandts, A. Scherpereel, Ch. Tulippe, P. Van Houtte,
P. Van Schil, C. Wachters, V. Westeel and J.P. Sculier
ABSTRACT: The present systematic review was performed under the auspices of the European
Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria
(surrogate markers), instead of survival, in determining treatment efficacy in patients with lung
cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy
was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature
with experts on these questions, it can be concluded that overall survival is still the best criterion for
predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if
not surrogates, for survival, despite limitations in their potential application: these include time to
progression, progression-free survival, objective response, local control after radiotherapy,
downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and
pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in
these recommendations are not currently adequate surrogates of survival in lung cancer.
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T
he European Lung Cancer Working Party
(ELCWP) is a cooperative research group
that has been actively involved in the per-
formance of academic clinical trials in thoracic
oncology for more than 30 yrs. Published reports
on trials, performed in various stages and with
various histological types of lung cancer, can be
found at the ELCWP website (www.elcwp.org).
The group is also involved in evidence-based
medicine and has published a number of meta-
analyses and systematic reviews [1], as well as
guidelines on the management of small (SCLC)
and nonsmall cell lung cancer (NSCLC) [2–6].
Improvement in survival or cure rates is the main
therapeutic goal in lung cancer management.
Other criteria of efficacy are commonly used as
primary end-points in clinical studies and rando-
mised trials, mainly concerning disease control
(duration and response) and quality of life (QoL)
or symptom control. During the past decade, new
techniques have emerged that have had some
impact on the therapeutic approach to lung cancer,
such as integration of positron emission tomogra-
phy into the staging strategy or use of tissue and
blood biomarkers for predicting survival prog-
nosis or treatment efficacy. The aforementioned
intermediate criteria have been proposed by some
researchers for use as primary efficacy criteria in
lung cancer. Nevertheless, it is currently not clear
whether these criteria can correctly predict overall
survival.
Intermediate criteria could provide some advan-
tages by replacing final end-points in clinical
trials. They can occur more frequently or sooner
than disease-specific mortality or overall survival.
The term ‘‘surrogate’’ is generally used in an in-
formal way to indicate that a biomarker or an
intermediate end-point can be used instead of the
final end-point of interest. A definition of surro-
gacy was proposed 20 yrs ago by PRENTICE [7],
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who has also defined operational criteria for validating the
value of a candidate surrogate: 1) a treatment should impact both
on the candidate surrogate and on the true clinical end-point;
and 2) the treatment effect on the surrogate should fully capture
the treatment effect on the true end-point. As this second
condition is difficult to prove and not practically suitable, other
definitions have emerged. As mentioned by BUYSE et al. [8], a
general consensus now exists that the validation of a surrogate
end-point can be carried out on the basis of a correlation
approach: first, a correlation should be demonstrated at the
individual level; that is, the surrogate end-point has to be shown
to be predictive of the true outcome; secondly, a correlation
should be obtained at the trial level (a correlation that can be
assessed through meta-analytical techniques). Nevertheless,
showing surrogacy remains a difficult exercise. As we expected
to find only scarce demonstrations of surrogacy in the field of
lung cancer, we searched for intermediate markers that are
‘‘simply’’ predictive/prognostic of the true outcome. Therefore,
we avoid in the present report the use of the term surrogate/
surrogacy and instead use the term ‘‘predictive’’, ‘‘prognostic’’
or ‘‘early’’ marker of treatment effect.
The following guidelines have been developed by the ELCWP
in order to determine if intermediate criteria can be used as
adequate predictive markers of overall survival in patients with
lung cancer. The main target of our group is to help clinicians
involved in the treatment of patients with lung cancer to integrate
study results from the literature into their routine practice.
METHODOLOGY
A preliminary symposium dedicated to this topic was held in
Brussels, Belgium, with the participation of a panel of experts
(10th Annual Day of Thoracic Oncology; March 21, 2009). This
led the ELCWP to make recommendations on the value of
intermediate criteria for predicting survival in lung cancer.
Initially, the level of evidence for the use of overall survival to
evaluate efficacy was reviewed. Furthermore, the guidelines
aimed to answer the following nine questions. 1) Can the
criteria of progression-free survival (PFS), time to progression
(TTP) and disease-free survival (DFS) be used to assess overall
survival? 2) Is objective morphological response to chemother-
apy a valid efficacy criterion, and which evaluation criteria
for response are to be used? 3) Are objective morphological
response criteria and local control applicable for the assess-
ment of overall survival in the case of chemoradiotherapy
(either sequential or concomitant)? 4) Can quality of life criteria
be used to predict overall survival, and which quality of life
scoring system should be applied? 5) Can downstaging after
induction chemotherapy predict overall survival, and which
assessment methodology needs to be used? 6) Do complete
resection and pathological TNM have a predictive role for
survival? 7) Can metabolic response, assessed by 18F-fluoro-
deoxyglucose gathering on positron emission tomography
(18F-FDG-PET or PET-CT), predict the efficacy of chemother-
apy? 8) What is the role of tissue biological markers for the
evaluation of overall survival? 9) What is the role of circulating
markers (molecules or cells) for the assessment of overall
survival? For each question, a definition of the intermediate
criteria is provided.
A review of the literature was performed using the Ovid
Medline system. This research was performed by a scientific
librarian, experienced in searching for medical and scientific
publications, and by physicians, experts in the treatment of
thoracic neoplasms and trained in evidence-based medicine,
assisted by a biostatistician.
Ovid Medline was searched using the OvidSP interface. Unless
otherwise stated, search terms were MeSH terms (medical
subject headings). MeSH terms were also combined with relevant
free-text terms that were searched for in all of the fields
containing text words, particularly in titles and abstracts. The
‘‘PICO’’ (population, intervention, comparator, outcome) model
for clinical questions was used to isolate the concepts included
in the question [9]. The corresponding search criteria were
translated into MeSH terms and free-text keywords (online
supplementary material). Completed search strategies included
the ‘‘P’’ and ‘‘O’’ criteria combined with one of the possible
intermediate markers listed in the online supplementary mater-
ial. Results were limited to those published in the period 1986 to
March 2010, except when the demonstration of overall survival
required retrieval of old surgical series or randomised trials in
SCLC. When the number of retrieved citations was too large,
additional limits were applied according to publication types and
levels of evidence, with randomised controlled trials and meta-
analyses having the strongest levels of support. In a few cases,
it was also necessary to reduce background noise by exclud-
ing studies focused on secondary lung cancers. Citations were
exported from Medline into reference manager databases to
allow the removal of duplicates and to facilitate the next selection
by reviewers. Exported references were scanned for relevance.
Articles were rejected on initial screening when titles, abstracts
and MeSH terms did not meet the inclusion criteria. The re-
maining articles were evaluated further for inclusion in the
current review. This search was supplemented by screening the
references of the selected articles and other literature known by
the research team and the ELCWP members.
To be eligible, a study had to fulfil the following criteria: to be
dedicated to the study of primary lung cancer, whatever the
stage or the histology; to deal with tumour staging, at least for
most of the patients included in the study, using the fourth,
fifth or sixth edition [10, 11] of the international staging system,
except for SCLC; to assess the relationship between one of the
intermediate criteria selected for the guidelines and survival, at
least in univariate analysis, whether it was the primary objective
of the publication or not; to be published in the English, French,
German or Dutch language literature, accessible to all co-
authors. Abstracts were excluded as they cannot be expected to
provide enough detail to allow the assessment of methodology
and/or survival information. However, we allowed the con-
sideration of unpublished studies if detailed results and meth-
odology allowing adequate interpretation for the current
guidelines were available, for example, an extensive oral presen-
tation on the website of a congress.
The recommendations were graded according to the Grades of
Recommendation Assessment, Development and Evaluation
(GRADE) system [12]; the methodology is summarised in
table 1. Selection of the publications was made according to this
system. The best level of evidence was systematically looked for.
The search was first limited to meta-analyses and randomised
controlled trials; if none was available, we looked for case–
control, cohort or prospective studies; finally, case reports, case
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series and expert opinion were considered. We graded the
recommendations as strongly or weakly, for or against using an
intervention. When no data were available to answer a question,
we decided that the recommendation was against the use of the
intervention.
A draft was written and discussed during three workshops of
the ELCWP (March 28 and October 16, 2009, and April 16, 2010)
by all the co-authors who reviewed the evidence found in
the literature. Thereafter, the guidelines were reviewed by the
ELCWP at a meeting held in Brussels in November 2010 and
approved by the panel of experts. The authors included medical
oncologists, thoracic surgeons, pneumologists, radiation oncolo-
gists and methodologists involved with the management of
thoracic malignancies (target audience) as recommended by
the AGREE collaboration group for the evaluation of guideline
quality (www.agreecollaboration.org). Remarks and suggestions
were then integrated into the final version of the guidelines. The
level of evidence, quality of evidence and grade of recommenda-
tion are listed in table 2.
PRELIMINARY QUESTION: THE USE OF OVERALL
SURVIVAL TO EVALUATE TREATMENT EFFICACY
According to the US Food and Drug Administration [13], survival
is defined as the duration between registration or randomisation
in a study and death from any cause (measured in intent-to-treat).
Cure is more difficult to define. The World Health Organization
(WHO) proposed a definition based on survival duration in
the group of patients with the disease, in comparison to that
observed in a general population with comparable demographic
criteria but without the disease [14]. Another option is to consider
that the patient is cured when he survives in good health for a
sufficient length of time comparable to that of a group of patients
with known low probability of recurrence.
The assessment of survival as a marker of treatment efficacy in
lung cancer patients can be evaluated in five instances: resectable
NSCLC, unresectable non-metastatic NSCLC, advanced and
metastatic NSCLC, and limited and extensive disease SCLC. This
evaluation is based on the review of the literature performed by
the ELCWP (www.elcwp.org) [2–6].
TABLE 1 Grades of Recommendation Assessment, Development and Evaluation system
First step: quality of evidence and definitions
4. High quality
Further research is very unlikely to change our confidence in the estimate of effect
3. Moderate quality
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
2. Low quality
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
1. Very low quality
Any estimate of effect is very uncertain




Any other evidence: very low
Decrease grade if:
Serious (-1) or very serious (-2) limitation to study quality
Important inconsistency (-1)
Some (-1) or major (-2) uncertainty about directness
Imprecise or sparse data (-1)
High probability of reporting bias (-1)
Increase grade if:
Strong evidence of association: significant relative risk of .2 (,0.5) based on consistent evidence from two or more observational studies, with no plausible
confounders (+1)
Very strong evidence of association: significant relative risk of .5 (,0.2) based on direct evidence with no major threats to validity (+2)
Evidence of a dose–response gradient (+1)
All plausible confounders would have reduced the effect (+1)
Third step: strength of recommendation
Fs: strong recommendation for using an intervention
Fw: weak recommendation for using an intervention
Aw: weak recommendation against using an intervention
As: strong recommendation against using an intervention
Determinants of strength: balance between desirable and undesirable effects; quality of evidence; values and preferences; costs (resource allocation)
Modified from [12] with permission from the publisher.
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1) For obvious ethical reasons, no randomised trials have been
performed comparing surgery alone to another medical treatment
or no therapy in operable patients with resectable NSCLC. The
level of evidence that surgery improves overall survival and
curability is based on historical data from retrospective and
prospective surgical series [15]. In accordance with other guide-
lines, surgery is the treatment of choice for stage I and II diseases
and remains an option for stage III NSCLC. Randomised trials and
meta-analyses have demonstrated that adjuvant and, to a lesser
extent, induction cisplatin-based chemotherapy, as well as UFT
(Uracil-Tegafur) in Japanese patients, prolonged survival in
comparison with surgery alone, at least in stage II and III
NSCLC [16, 17].
2) The evidence of the curative role of radiotherapy alone for
unresectable non-metastatic NSCLC comes from control arms
of randomised trials of treatment with irradiation alone or by
extrapolation from series of inoperable patients with resectable
NSCLC (stages I and II). A 5-yr survival of 4–10% was docu-
mented [18, 19]. The addition of chemotherapy to curative
radiotherapy, administered either sequentially or concomi-
tantly, yielded improved survival and cure rates in comparison
with those for radiotherapy alone. This evidence came from
randomised trials and meta-analyses [20–25].
3) At least 15 randomised trials and five meta-analyses con-
firmed that survival improvement is obtained with first-line
TABLE 2 Summary of the recommendations based on level of evidence, quality of evidence and grade of recommendation







1.1) Time-to-progression is an intermediate marker for overall survival in advanced NSCLC treated
with first-line chemotherapy
MA 3 Fs
1.2) Progression-free survival is a potential intermediate marker for survival in the setting of
docetaxel or vinca-alcaloids first-line based regimens
MA 2 Fw
2.1) Objective response is an intermediate criterion for overall survival in advanced NSCLC treated
with first-line or salvage chemotherapy
MA/RT 4 Fs
2.2) Objective response is an intermediate criterion for overall survival in extensive disease SCLC
treated with first-line chemotherapy
MA/ReS 2 Fw
2.3) Objective response is a potential intermediate criterion for overall survival in operable NSCLC
treated with induction chemotherapy and in locoregionally advanced NSCLC treated by
chemotherapy and radiotherapy
ReS 2 Fw
3.1) Although commonly used, conventional criteria for response assessment of primary lung tumour
treated by (chemo)radiotherapy cannot be used as intermediate criteria for survival
ReS 1 Aw
3.2) Local control, for which the definition has to be clarified, may be a possible intermediate
criterion for overall survival
ReS 1 Fw
4) Response at the QoL level cannot be recommended as an intermediate criterion for overall
survival due to a lack of robust data
ReS 1 Aw
5) Although not strictly demonstrated, there are numerous arguments from subgroup analyses of
randomised trials and retrospective studies that mediastinal downstaging and, to a lesser extent,
TN downstaging are associated with better survival in locally advanced NSCLC treated by
induction chemotherapy or chemoradiotherapy before surgery
ReS 2 Fw
6.1) Complete resection is a prognostic factor for survival in resected NSCLC and can be used as an
intermediate criterion for overall survival
Cohort/ReS 3 Fs
6.2) Pathological TNM is a prognostic factor for survival in resected NSCLC and can be used as an
intermediate criterion for overall survival
Cohort 3 Fs
7) Metabolic response assessed by PET scan should not be used for the routine assessment of
response to treatment in lung cancer patients in place of morphological criteria
ReS/CS 1 Aw
8) Tissue biological markers have not to be used for evaluation of treatment efficacy and are not
adequate intermediate criteria for overall survival in lung cancer patients
CS 1 Aw
9.1) It is suggested that some circulating markers (CEA, Cyfra 21-1 and pro-GRP, and to a lesser
extent NSE, CA-125 and CA19-9), used as single criterion to assess overall survival, could be
adequate intermediate criteria for survival in lung cancer patients
ReS 2 Fw
9.2) The persistence of circulating tumour cells in NSCLC may have a prognostic impact on further
survival
Cohort 1 Fw
NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer; QoL: quality of life; PET: positron emission tomography; CEA: carcinoembryonic antigen; pro-GRP:
pro-gastrin releasing peptide; NSE: neurone-specific enolase; MA: meta-analysis; RT: randomised trial; ReS: retrospective studies; CS: case series; Fs: strong
recommendation for using an intervention; Fw: weak recommendation for using an intervention; Aw: weak recommendation against using an intervention.
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chemotherapy in comparison with best palliative care alone in
advanced and metastatic NSCLC [20, 26–29]. Two randomised
trials demonstrated that salvage chemotherapy with docetaxel
or erlotinib also improved survival in comparison with pallia-
tive care [30, 31].
4) The effect on survival of chemotherapy for first-line treatment
of SCLC was first observed in old randomised trials comparing
alkylating agents with inert compounds, which showed im-
proved survival with cyclophosphamide monotherapy [32]. Cur-
rently, multiple drug administration has become the standard
chemotherapy. In this instance, two meta-analyses demonstrated
that cisplatin- and/or etoposide-based chemotherapy is more
effective and yielded better survival than other regimens [33, 34].
In limited disease SCLC, 15 randomised trials and three meta-
analyses demonstrated that the addition of radiotherapy to
chemotherapy increased survival in comparison with chemother-
apy alone [35–37]. There has been only one randomised trial
comparing topotecan with palliative care for salvage treatment,
with improved survival with chemotherapy [38].
Overall survival has the advantage of being unambiguous (the
patient is dead or alive). Assessing the distribution of survival
duration in a group of patients makes use of probability theory
and not simple mortality rate. The main disadvantages of this
are the impact of subsequent treatment on overall survival and,
in the case of long-term survival, the follow-up duration and
the risk of loss to follow-up.
In conclusion, an improvement in overall survival or rate of
cure is widely accepted as an important goal of lung cancer
therapy and is generally considered as the leading criterion of
efficacy of a treatment in lung cancer patients.
The subsequent questions are not listed in any particular
hierarchical order.
QUESTION 1: CAN THE CRITERIA OF PFS, TTP AND DFS
BE USED TO ASSESS OVERALL SURVIVAL?
PFS is defined as the duration between registration or rando-
misation in a study and the first objective aggravation of the
disease or death. TTP is the time from study enrolment to the
first date of disease progression. DFS is the period between
registration or randomisation in a study and tumour recurrence
or death. This criterion is mainly used in the adjuvant and
surgical settings when no more target lesions are available [39].
To date, two meta-analyses have been published assessing the
predictive value of TTP on overall survival in lung cancer patients
[40, 41]. A pooled analysis of selected randomised controlled trials
was orally presented during the 2008 American Society of Clin-
ical Oncology (ASCO) meeting [42]. Although not published in
full, it was selected for the present guidelines because detailed
results and methodology were available on the ASCO website.
The results of these three studies are reported in table 3. The three
studies dealt with advanced NSCLC treated with first-line chemo-
therapy in randomised controlled trials. In the two published
studies [40, 41], a statistically significant correlation between TTP
and overall survival was detected, although it was of limited
amplitude. In the study reported by HOTTA et al. [41], the median
TTP ratio accounted for less than half the variability (41%) of
the median survival ratio. To predict a statistically significant
improvement in the survival time at the p-value of 0.05, an
increase in the median TTP of 1.8 months must be observed for
trials with 750 patients, and 2.2 months and 3.3 months for those
with 500 and 250 patients, respectively [40]. Some evidence for a
relationship between PFS and overall survival is provided in the
latter study [42]: a 30% reduction in the risk of progression
assessed by PFS predicts a statistically significant effect on overall
survival in patients with advanced NSCLC treated with first-
line docetaxel- or vincalcaloid-containing regimens. It must be
pointed out that this positive association between improved PFS
and further increase in survival was recently not confirmed in
randomised trials comparing chemotherapy to epidermal growth
factor receptor tyrosine kinase inhibitors (TKIs), despite a high
hazard ratio for PFS favouring the TKI treatment [43–45].
We did not find meta-analyses or specific studies with, as their
primary objective, the assessment of PFS, TTP or DFS as an
intermediate marker for overall survival in resectable NSCLC
treated by surgery with or without chemotherapy, in unre-
sectable NSCLC treated by chemoradiotherapy, in NSCLC
receiving salvage chemotherapy, and in SCLC.
TABLE 3 Meta-analyses or pooled analysis assessing the role of time-to-progression and progression-free survival as
intermediate end-point for overall survival in lung cancer patients









JOHNSON et al. [40] TTP Advanced
NSCLC
RCT
of first line CT
1966–2005 191 44125 r250.19
p50.0003
Multivariate analysis





of first line CT
1987–2002 54 23457 r250.33
p,0.01
Multivariate analysis
BUYSE et al. [42] PFS Advanced
NSCLC
RCT
of first line CT#
2003–2006 7 2838 r250.61
TTP: time-to-progression; NSCLC: nonsmall cell lung cancer; RCT: randomised controlled trial; CT: chemotherapy; PFS: progression-free survival. #: RCT comparing
docetaxel to vincalcaloids regimens.
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PFS, TTP and DFS have potential advantages in prospective
studies, by reducing the number of patients to be accrued, and the
follow-up and study durations, as well as in alleviating the effect of
subsequent treatment on the study end-point. There are numerous
disadvantages related to the parameters used, as follows. Which is
the best criterion determining objective progression? How do you
consider disagreements on evaluation criteria among investiga-
tors? How do you manage the absence of blinding in interpreta-
tion of results? Most importantly, all these parameters are highly
dependent on the duration between two disease assessments
and the type of assessment, which must be independent of the
treatment arm.
Recommendations
1) TTP is an intermediate marker for overall survival in
advanced NSCLC treated with first-line chemotherapy. Level
of evidence: meta-analyses; quality of evidence: 3; grade of
recommendation: Fs.
2) PFS is a potential intermediate marker for survival in the
setting of docetaxel or vinca-alcaloid first-line regimens. Level of
evidence: meta-analyses; quality of evidence: 2; grade of recom-
mendation: Fw.
Statements
More evidence is needed to confirm that TTP or PFS and DFS are
intermediate criteria predicting overall survival in the following
settings: in patients with resectable NSCLC treated by surgery
with or without chemotherapy, with unresectable NSCLC treated
by chemoradiotherapy, with NSCLC treated by salvage chemo-
therapy and with SCLC. DFS cannot be recommended as an
intermediate marker for overall survival, owing to the lack of data.
QUESTION 2: IS OBJECTIVE MORPHOLOGICAL
RESPONSE TO CHEMOTHERAPY A VALID EFFICACY
CRITERION, AND WHICH EVALUATION CRITERIA FOR
RESPONSE ARE TO BE USED?
The first definition of objective response was proposed by C.G.
Zubrod in 1960. Currently, three systems are available (table 4).
All are based on expert opinions without adequate statistical
methodology applied for choosing the cut-off determining the
different categories of response. The WHO system was published
in 1979 [14]. The South West Oncology Group (SWOG) used its
own definition, close to that of the WHO, in its studies [46].
RECIST (Response Evaluation Criteria In Solid Tumours) was
developed in 2000, to be used in clinical studies [47]. The main
differences between RECIST and WHO/SWOG criteria were the
following: use of unidimensional instead of bidimensional
measurement, limitation in the number of target lesions (max-
imum five per organ with an overall maximum of 10 lesions), and
different cut-offs for response and progression. A new version of
RECIST has recently been published [48]. The main modifications
of version 1.1 are that a maximum of two lesions per organ are
considered and that a complete response on lymph nodes is
defined as a node no more than 10 mm in short axis.
Seven meta-analyses have been published to date that assess,
as the primary objective of the study, the relationship between
objective response to chemotherapy and survival [40, 49–54].
Objective response and/or disease control (objective response
plus stable disease) predict improvement in overall survival in
the following situations: advanced NSCLC receiving first-line
or salvage chemotherapy and extensive disease SCLC treated
by first-line chemotherapy (table 5). In three meta-analyses,
the impact of response on overall survival was quantified.
A statistically significant (p,0.05) increase in overall survival
could be observed for an increase in response rate of 18%
requiring 750 patients to be included in randomised trials. This
value increases to 21% and 30% if the number of patients is 500
or 250, respectively [40]. In two other studies, each 1% increase
in response rate resulted in an improvement in median
survival time of 0.26 months in patients receiving TKI [54] or
0.07 months with salvage chemotherapy [51]. When specified,
the evaluation criteria for response were most often those
of the WHO and RECIST. However, no formal comparison
between the two systems has been performed for lung cancer
patients. We also looked at large retrospective studies pooling
TABLE 4 World Health Organization (WHO), South West Oncology Group (SWOG) and RECIST (Response Evaluation Criteria In
Solid Tumours) criteria for response assessment
WHO SWOG RECIST#
Complete response Complete disappearance of all
measurable and assessable tumoural
lesions not less than 4 weeks apart
Complete disappearance of all measurable and
assessable tumoural lesions, including normalisation
of markers and other abnormal laboratory values for
at least 3–6 weeks
Complete disappearance of all tumoural
lesions for at least 4 weeks
Partial response Decrease o50% of the product of
the two greatest perpendicular
diameters for at least 4 weeks
Decrease o50% of the product of the two greatest
perpendicular diameters for at least 3–6 weeks
Decrease o30% of the sum of
the greatest diameters
Stable disease No response or progression Decrease ,50% or increase ,50% (,10 cm2) of the
product of the two greatest diameters for at least 3–6
weeks
No response or progression
Progression Increase .25% of the product of the
two greatest perpendicular diameters
or appearance of a new lesion
Increase .50% or .10 cm2 of the product of the two
greatest diameters or appearance of a new lesion or
clear aggravation of any assessable lesion
Increase .20% of the sum of the
greatest diameters or appearance
of a new lesion
Data taken from [14, 46, 47]. #: the final evaluation according to RECIST criteria takes into account the response on target and non-target lesions.
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prospective trials performed for lung cancer (table 6) [55–58].
Objective response was also found to be a significant predictor
for better survival in advanced and metastatic NSCLC [55–57]
and in SCLC [58], whatever the stage of the disease, treated by
chemotherapy.
No meta-analyses or randomised trials having the evaluation
of response as an intermediate criterion for survival were
available in the following clinical settings: induction chemother-
apy for operable NSCLC, sequential or concomitant chemo-
radiotherapy for locoregionally advanced NSCLC, and limited
disease and recurrent SCLC. Better survival was found in
patients with NSCLC presenting with an objective response to
induction chemotherapy before surgery or to treatment for loco-
regionally advanced NSCLC, induction chemotherapy before
radiotherapy, chemoradiotherapy, or radiotherapy alone [59–64].
The level of evidence was from analyses of secondary objectives
of randomised trials published on each topic (table 6) and phase
II studies [66–74]. We found only one study in SCLC showing that
patients with complete response had longer survival than those
with partial response or no change, those progressing under first-
line treatment with chemotherapy or chemoradiotherapy having
the worst prognosis [65].
There are few formal comparisons allowing determination
of which evaluation criteria are to be used. In the RECIST
publication [47], a comparison between RECIST 1.0 and WHO
criteria did not find any significant difference for assessing
objective response or progression, whether considering the
whole population or only lung cancer patients. Further studies
have been performed in patients with lung cancer, which are
summarised in table 7. Overall, there was no significant
difference between the two systems of evaluation for response
determination [47, 75–79].
Recommendations
1) Objective response is an intermediate criterion for overall
survival in advanced NSCLC treated with first-line or salvage
chemotherapy. Level of evidence: meta-analyses and rando-
mised trials; quality of evidence: 4; grade of recommendation: Fs.
2) Objective response is an intermediate criterion for overall
survival in extensive disease SCLC treated with first-line chemo-
therapy. Level of evidence: meta-analyses and retrospective
studies; quality of evidence: 2; grade of recommendation: Fw.
3) Objective response is a potential intermediate criterion for
overall survival in operable NSCLC treated with induction
chemotherapy and in locoregionally advanced NSCLC treated by
chemotherapy and radiotherapy. Level of evidence: retrospective
studies; quality of evidence: 2; grade of recommendation: Fw.
Statements
More evidence is needed to confirm that objective response
is an intermediate criterion predicting overall survival in the
following settings: operable NSCLC treated with induction
chemotherapy, locoregionally advanced NSCLC and limited
disease SCLC treated by chemotherapy and radiotherapy.
WHO and RECIST 1.0 criteria appear to have the same efficacy
in predicting objective response in locoregionally advanced
and metastatic NSCLC. On the basis of the available data, it is not
possible to determine the best response criterion to be used in
other settings related to lung cancer management, the equiva-
lence of WHO and RECIST criteria having to be confirmed in
larger studies.
The cut-off point to define response/progression, as proposed by
the WHO and the RECIST systems, needs validation assessment.
TABLE 5 Meta-analyses assessing response as an intermediate marker for overall survival in lung cancer
Patients n Effect on survival U/M Response criteria
NSCLC treated by chemotherapy#
SEKINE et al. [52] 6768 OR: r250.36 (p50.00003) M
TSUJINO et al. [54] 6171 OR: p,0.0001 (qMST 0.26 month/q1% OR) U WHO, RECIST
DCR: p50.003 (qMST 0.17 month/q1% DCR)
Advanced NSCLC receiving first line chemotherapy
JOHNSON et al. [40] 44125 OR: r250.16 (p,0.0001) M WHO
HOTTA et al. [50] 43551 OR: r50.08 (p,0.0001) M
DCR: r50.08 (p,0.0001)
SHANAFELT et al. [53] 2794 OR: r250.22 (qMST 1 week/q3.3% OR) U
NSCLC receiving salvage chemotherapy
HOTTA et al. [50] 4318 OR: p50.69 M
DCR: p50.013
KURATA et al. [51] 4292 OR: p,0.001 (qMST 0.07 month/q1% OR) M
SD: p50.04 (qMST 0.038 month/q1% SD)
Extensive disease SCLC receiving first line chemotherapy
HOTTA et al. [49] 8779 OR: r250.33 U WHO, RECIST, other
U: results obtained in univariate analysis; M: results obtained in multivariate analysis; NSCLC: nonsmall cell lung cancer; OR: overall response; MST: median survival time;
WHO: World Health Organization; RECIST: Response Evaluation Criteria In Solid Tumours; DCR: disease control rate; SD: stable disease; SCLC: small cell lung cancer.
#: first line and salvage chemotherapy combined.
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In the context of maintenance therapy, disease control rate
(response plus stable disease) needs validation assessment.
QUESTION 3: ARE OBJECTIVE MORPHOLOGICAL AND
METABOLIC RESPONSE CRITERIA AND LOCAL
CONTROL APPLICABLE TO ASSESS OVERALL
SURVIVAL IN THE CASE OF CHEMORADIOTHERAPY
(EITHER SEQUENTIAL OR CONCOMITANT)?
There are many problems when defining response by conven-
tional criteria (WHO and/or RECIST) due to pneumonitis and
fibrosis modifications induced by thoracic irradiation, which
must be differentiated from residual neoplastic tissue. As these
changes are time-related and increase by the use of radio-
sensitising chemotherapeutic agents, timing of evaluation after
treatment could influence response assessment.
The role of new evaluation techniques like PET(-CT) was assessed
in a few small retrospective studies. In 73 NSCLC patients treated
by radical radiotherapy or chemoradiotherapy, there was poor
agreement between PET and CT response assessment (kappa 0.35)
using respectively European Organization for Research and
Treatment of Cancer (EORTC) and WHO criteria. In multivariate
analysis, only PET response was associated with survival (p,
0.0001) [80]. In a second study including 50 patients treated with
induction chemoradiotherapy, followed by surgery in 37 cases,
change in standardised uptake value (SUV) on PET-CT after
induction treatment was not related to survival (p50.75) [81].
Lastly, SUVmax after induction chemoradiotherapy predicted sur-
vival in operated patients with NSCLC. The median survival was
longer for the patients with SUVmax ,4 than in those with SUV
more than 4, namely, 56 months versus 19 months (p,0.001) [82].
Local control is another commonly used approach to under-
take intrathoracic response assessment. In a consensus expert
conference held in Bruges, Belgium in 1993, the proposals for
defining lung cancer local control after thoracic irradiation
were complete disappearance of all radiographic abnormali-
ties by chest film CT and residual radiographic abnormality
assessed by chest CT at 3 and 6 months, which then remains
stable for an additional 6 months or more. This definition has
never been the topic of a validation study.
Literature on this question is relatively disappointing. We
found only a few retrospective studies or secondary analyses
of randomised trials assessing the association between local
control and survival in lung cancer. BIRCH et al. [83] observed
for limited disease SCLC that survival was longer for patients
achieving local control after chemoradiotherapy than for those
who did not. In a small retrospective study including limited
and extensive disease SCLC, COX et al. [84] had the same
observation. DOSORETZ et al. [85] showed that local control
resulted in improved survival in irradiated medically inoper-
able NSCLC. In a retrospective study of Radiation Therapy
Oncology Group randomised trials, local control was associated
with significantly better survival [86]. However, the ELCWP
could not confirm these results in a phase III trial comparing
chemotherapy to chemotherapy followed by radiotherapy in
stage III unresectable NSCLC [87]. A significant increase in local
control duration was obtained in the combination arm: median
of 158 weeks versus 31 weeks, with respective 2-yr rates of 57%
and 24% (p50.0007). This better local control duration did not
result in a statistically significant increase in survival duration:
median of 54 weeks (95% CI 43–73 weeks) versus 42 weeks (95%
CI 35–51 weeks), with 2-yr survival rates of 22% (95% CI 11–
33%) and 18% (95% CI 8–28%).
Recommendations
1) Although commonly used, conventional criteria for response
assessment of primary lung tumours treated by (chemo)
radiotherapy cannot be used as intermediate criteria for
survival. Level of evidence: retrospective studies; quality of
evidence: 1; grade of recommendation: Aw.
2) Local control, for which the definition has to be clarified, is a
possible intermediate criterion for overall survival. Level of
evidence: retrospective studies; quality of evidence: 1; grade of
recommendation: Fw.
Statement
The roles of conventional WHO or RECIST criteria, of meta-
bolic response criteria (PET imaging) and of local control as
intermediate criteria in the context of lung cancer treated by
(chemo)radiotherapy have to be assessed in prospective studies.
QUESTION 4: CAN QUALITY OF LIFE CRITERIA BE USED
TO PREDICT OVERALL SURVIVAL? WHICH QUALITY OF
LIFE SCORING SYSTEM HAS TO BE APPLIED?
We identified some data in the literature related to this
topic, although there are many papers suggesting a prognostic
role for baseline QoL data [88–90]. Several scoring systems
exist and have been validated with the availability of mod-
ules dedicated to lung cancer symptoms and treatment side-
effects. Those which have been studied in association with the
TABLE 7 Comparison between World Health Organization (WHO) and RECIST (Response Evaluation Criteria In Solid Tumours)
1.0 for response assessment in lung cancer
Study P/R Patients n Population RR-RECIST% RR-WHO% PD-RECIST% PD-WHO%
THERASSE et al. [47] R 1197 ND 32 32
WERNER-WASIK et al. [75] P 22 Locally advanced NSCLC 87 87
CORTES et al. [76] R 164 Metastatic NSCLC 52 52 26 26
WATANABE et al. [77] R 120 Metastatic NSCLC 19 20 13 17.5
PARK et al. [78] R 28 NSCLC 39 43 25 29
KONISHI et al. [79] R 32 38 47 6 6
P: prospective study; R: retrospective study; RR: response rate; PD: progressive disease; ND: no data; NCSLC: nonsmall cell lung cancer.
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predictive value of QoL on other outcomes (response to
chemotherapy, PFS and survival) are the EORTC QoL core
questionnaire (30 items) complemented by the lung cancer
module LC13 [91, 92] and the Functional Assessment of Cancer
Therapy – Lung (FACT-L) with a module specific for the
symptoms of the disease (LCSS) [93]. Before looking at this
predictive value, it is relevant to define what is meant by a
response at the QoL level. OSOBA et al. [94] defined an increase
in the overall EORTC QoL score of .10 points as a response,
a decrease of .10 points as a progression, and intermediate
results as stabilisation, on the basis of concordance between
QoL score evolution and a subjective question. CELLA et al. [95]
proposed a definition of response for two outcomes for the
LCSS score (from 0 to 28, with increasing values for increasing
QoL) and the TOI (Trial Outcome Index, which is the sum of
LCSS and functional and physical wellbeing scales, from 0 to
84). For the first outcome, an increase of 2–3 points is needed
and, for the TOI, an increase of 5–7 points is required.
Definitions of stabilisation and progression are derived from
these thresholds. This proposal resulted from the analysis of a
clinical trial and used the association between QoL evolution
and response to chemotherapy or PFS.
One report on a meta-analysis suggests that an association
between QoL and radiological response exists (positive
correlation), but this meta-analysis was not dedicated to lung
cancer and suffered from a serious selection bias: out of more
than 350 studies identified by the literature search, only 21
could be included in the quantitative review [96].
ETON et al. [97] have shown, for patients with advanced lung
cancer, using the database of a clinical trial and the FACT-L
scoring system, that classification into four groups (I: high
baseline FACT-L score with improvement; II: high baseline with
deterioration; III: low baseline with improvement; IV: low
baseline with deterioration) has prognostic value for TTP and
overall survival. Group I had the best results, followed by group
II, group III and group IV (p,0.001).
CELLA et al. [98] studied the QoL evolution among patients
treated in the IRESSA Dose Evaluation in Advanced Lung
Cancer (IDEAL)-2 trial testing gefitinib as second-line treatment
for NSCLC. The patients with a QoL response (.2 point im-
provement on the LCSS scale) had a significantly prolonged
survival compared with the other patients (median of 13 months
compared with 5 months after a landmark of 8 weeks; p,0.001).
Data from IDEAL-1 point in the same direction [99]. In the Iressa
NSCLC Trial Assessing Combination Treatment (INTACT) trials
looking at the addition of gefitinib to a chemotherapy regimen in
the first-line setting, the association between QoL and anti-
tumoural response has been studied using the EORTC QoL ques-
tionnaire. The associations with different scales (overall scale,
physical scale, pain, cough and dyspnoea) and response were all
significant. However, we do not have any available data about
the value of QoL response for PFS or overall survival [100, 101].
Recommendation
Response at the QoL level cannot be recommended as an inter-
mediate criterion for overall survival owing to a lack of robust
data. Level of evidence: retrospective studies; quality of evidence:
1; grade of recommendation: Aw.
Statement
The association between response at the QoL level and long-term
outcomes, as suggested in some instances (recurrent NSCLC
treated with gefitinib), needs further investigation, including ade-
quate determination of cut-off points defining a response, and of
the most appropriate questionnaire.
QUESTION 5: CAN DOWNSTAGING AFTER INDUCTION
CHEMO(RADIO)THERAPY PREDICT OVERALL
SURVIVAL, AND WHICH ASSESSMENT METHODOLOGY
NEEDS TO BE USED?
Downstaging can be defined as a shift to a lower disease stage
after a treatment. In NSCLC, studies assessing the prognostic
role of downstaging on survival after induction chemother-
apy have been performed at the mediastinal (N stage) or the
TN level. The literature is generally heterogeneous. Inclusion
criteria are quite different from one study to another according
to stage, mediastinal evaluation (clinical or pathological defini-
tion), type of treatment (induction chemotherapy or chemo-
radiotherapy before surgery; nonsurgical treatment only) and
type of downstaging (N or TN). Most of the publications are
case series or retrospective analyses of phase II studies of small
sample size. We found only two phase III trials in which these
questions were retrospectively analysed. The first trial com-
pared the role of surgery to radiotherapy in stage IIIA patho-
logical N2 NSCLC treated by induction chemotherapy [102]. In
the surgery arm including 154 randomised patients, mediastinal
downstaging was an independent prognostic factor for survival
in multivariate analysis (p50.04). In the second trial, comparing
chemoradiotherapy alone to chemoradiotherapy followed by
surgery in stage III pathological N2 NSCLC, mediastinal
downstaging in the surgical group (164 patients) was associated
with better survival in univariate analysis with median survival
times for pathological N0 and N1–3 of 34.4 months and
26.4 months, respectively (p,0.0001) [103].
Mediastinal downstaging in NSCLC has been assessed by
noninvasive (CT and PET scan), minimally invasive (oesopha-
geal (EUS) or endobronchial (EBUS) endoscopic procedures),
and invasive procedures (re-mediastinoscopy and video-assisted
thoracoscopic surgery (VATS)). In its 2007 guidelines, the
European Society of Thoracic Surgeons did not recommend a
particular procedure for restaging but recommended that cyto-
histological proof be obtained by a minimally invasive or invasive
procedure, depending on the availability and specific expertise of
staff at the centre [104]. The literature on mediastinal restaging
was recently reviewed [105]. Sensitivity, specificity, false-negative
and false-positive rates for mediastinal CT restaging were on
average 63%, 70%, 31% and 34%, respectively. Respective values
for PET scan were 63%, 70%, 26% and 34%. Combined PET-CT
seems more adequate, with sensitivity of 62–77%, specificity of
88–92%, false-negative rate of 20–25%, false-positive rate of 7–
25%, and an accuracy of 79–83% [106, 107]. Few studies have
assessed the role of minimally invasive procedures for mediast-
inal re-staging. EUS was evaluated in three very small studies,
EBUS in one, and transbronchial needle aspiration in another.
Average sensitivity and false-negative rates were 84% and 14%,
respectively. Re-mediastinoscopy is technically challenging due
to adherence and fibrosis. In a few studies, the sensitivity of this
technique was 63%, with 100% specificity and accuracy of 84–93%.
The false-negative rate was 22%. VATS was assessed in a small
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series of 70 patients [108]. The procedure was unsuccessful in 17
patients owing to fibrosis. Reported sensitivity, specificity and
negative predictive value were 75%, 100% and 76%, respectively.
Recommendation
Although not strictly demonstrated, there are numerous asser-
tions from subgroup analyses of randomised trials and retro-
spective studies that mediastinal downstaging and, to a lesser
extent, TN downstaging are associated with better survival in
locally advanced NSCLC treated by induction chemotherapy
or chemoradiotherapy before surgery. Level of evidence: retro-
spective studies; quality of evidence: 2; grade of recommenda-
tion: Fw.
Statements
The association between downstaging after induction chemo-
therapy (or chemoradiotherapy) and long-term outcomes
should be confirmed and needs further investigation in
adequately powered prospective studies.
PET-CT is the recommended noninvasive technique for media-
stinal restaging, being more precise than CT scan, which appears
insufficiently accurate in this setting. When pre-operative patho-
logical persistent mediastinal neoplastic infiltration has to be
confirmed, minimally invasive or invasive techniques are feasi-
ble, each one appearing with similar efficacy. The choice of the
technique will depend on the local expertise and the initial
technique used for demonstrating mediastinal invasion.
QUESTION 6: DO COMPLETE RESECTION AND
PATHOLOGICAL TNM HAVE A PREDICTIVE ROLE FOR
SURVIVAL?
The basis of the definition of complete resection is the Union
Internationale Contre le Cancer (UICC) residual tumour classi-
fication (R classification) [109]. R0 category consists of the absence
of residual tumour in the primary site, lymph nodes and distant
sites, which appears insufficient in lung cancer, and is mainly for
the mediastinal definition of complete resection. The Complete
Resection subcommittee of the International Association for
the Study of Lung Cancer (IASLC) Staging Committee, after an
extensive review of the literature, proposed the definition of
complete resection based on an international consensus [110]:
‘‘Complete resection requires all of the following: free resection
margins proved microscopically; systematic nodal dissection or
lobe-specific systematic nodal dissection; no extracapsular nodal
extension of the tumour; and the highest mediastinal node
removed must be negative. Whenever there is involvement of
resection margins, extracapsular nodal extension, unremoved
positive lymph nodes, or positive pleural or pericardial effusions,
the resection is defined as incomplete. When the resection
margins are free and no residual tumour is left, but the resec-
tion does not fulfil the criteria for complete resection, there is
carcinoma in situ at the bronchial margin, or positive pleural
lavage cytology, the term uncertain resection is proposed.’’ R1 is
defined as a persistence of microscopic tumour tissue and R2 as
macroscopic incomplete resection.
The level of evidence of the prognostic role of R0 in NSCLC is
relatively low. There have been many studies derived from
retrospective analyses of phase II and surgical series, mainly
including stage IIIA-N2 NSCLC. In most of them, R0 was a
predictive factor for survival in either univariate or multivariate
analysis. We found only one phase III trial in which R0 was
evaluated in multivariate analysis as a secondary end-point [102].
In 154 stage IIIAN2 NSCLC patients receiving induction
chemotherapy followed by surgery, R0 was an independent
prognostic factor for survival with median survival times of 24
(R0) versus 12 months (R1/R2). For a few large series, including
pathological stage I–IV NSCLC patients, incomplete resection
was reported as a poor prognostic factor for survival in multi-
variate analysis. Involved resection margins were associated with
an increased risk of death (hazard ratio 1.49; p,0.001) among
3,211 patients from a Norwegian registry [111]. In another
surgical series of 836 patients, a hazard ratio of 8.2 (p,0.001) was
observed in R1/R2 in comparison with R0 cases [112]. Doubling
or tripling of the risk of death was observed in a series of 446
patients (p,0.01) [113].
The IASLC reported the largest recent studies, assessing the
prognostic role of pathologic TNM in 9137 resected NSCLC. In
multivariate analysis, pathological stage using the seventh
version proposed by the IASLC was a significant prognostic
factor for survival (p,0.0001) [114]. In large series or registry
studies of more than 500 patients, pTNM [111, 115–117] and,
when analysed separately, pT or pN [112, 118, 119], were
found to be independently associated with survival. Lastly,
pTNM, pT, or pN was found to be a significant predictor for
survival in six randomised trials assessing the role of adjuvant
chemotherapy after surgery and considering pathological stage
in analyses of prognostic factors [120–125]. In these studies, the
fifth version of the UICC and American Joint Committee on
Cancer Staging system was most often used, although the
fourth version was applied in three studies.
Recommendations
1) Complete resection is a prognostic factor for survival in
resected NSCLC and can be used as an intermediate criterion
for overall survival. Level of evidence: cohort and retrospective
studies; quality of evidence: 3; grade of recommendation: Fs.
2) Pathological TNM is a prognostic factor for survival in
resected NSCLC and can be used as an intermediate criterion
for overall survival. Level of evidence: cohort studies; quality
of evidence: 3; grade of recommendation: Fs.
Statement
The definition of complete resection proposed by the Complete
Resection subcommittee of the IASLC is recommended.
QUESTION 7: CAN METABOLIC RESPONSE, ASSESSED
BY 18F-FLUORODEOXYGLUCOSE GATHERING ON
POSITRON EMISSION TOMOGRAPHY (18F-FDG-PET OR
PET-CT), PREDICT THE EFFICACY OF
CHEMOTHERAPY?
In a systematic review of the literature with a meta-analysis
[126, 127], primary tumour SUVmax measured on 18F-FDG-PET
has been shown to have prognostic value in NSCLC. This
observation needs to be confirmed by a multivariate analysis
taking into account the known prognostic factors; nevertheless,
it strongly suggests than PET may be more useful than only
providing imaging.
PET has been proposed for the assessment of response to
chemotherapy. Criteria were defined in 1999 by the EORTC PET
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Study Group [128]. A complete metabolic response is complete
resolution of 18F-FDG uptake within the tumour volume so that
it is indistinguishable from surrounding normal tissue. A partial
metabolic response consists of the reduction of a minimum of
15% in tumour SUV after one cycle of chemotherapy, and greater
than 25% after more than one treatment cycle. A reduction in the
extent of the tumour uptake is not a requirement for partial
metabolic response. A stable metabolic disease is an increase in
tumour SUV ,25% or a decrease ,15% and no visible increase
in the extent of tumour uptake (20% in the longest dimension). A
progressive metabolic disease consists of an increase in tumour
SUV .25% within the tumour region defined on the baseline
scan, visible increase in the extent of tumour uptake (20% in
the longest dimension), or appearance of new FDG uptake in
metastatic lesions. For the experts, 25% was found to be a useful
cut-off point, but there was a need for reproducibility analysis to
determine the appropriate cut-off for statistical significance.
10 yrs later, that analysis has yet to be performed.
Data on lung cancer in this context are limited and heterogeneous.
A few small studies have assessed the predictive effect of
metabolic response for further survival. In a series of 57 patients
with advanced NSCLC treated by chemotherapy, changes in SUV
have been shown to have relatively similar adequacy to changes
in tumour/muscle ratio and to be better than changes in net-
influx constants [129]. In another series of 51 NSCLC patients (15
treated by induction chemotherapy and 31 by palliative chemo-
therapy), metabolic response assessed by the EORTC criteria was
not associated with a significant difference in survival, while it
became significant when patients were divided into two groups
according to the median change in SUV [130]. In a group of
30 patients with stage IIIAN2 NSCLC treated by induction
chemotherapy, the best cut-off in decrease of SUVmax to predict
5-yr survival was 60%; a decrease of 25% was not discriminatory
[131]. In a systematic review of the literature about the prediction
of histopathological response and further survival in stage III
disease treated by induction treatment, DE GEUS-OEI et al. [132]
showed the great heterogeneity of studies in terms of cut-off of
SUV used and definition of pathologic response. In the series
reported above, DOOMS et al. [131] defined a group with good
prognosis by combining pathological (pN0 or pN2 with ,10%
cancer cells in mediastinal lymph nodes) and metabolic (.60%
decrease of SUV max in the primary tumour) criteria. Finally,
complete (but not partial) metabolic response has been associated
with better survival in a series of 31 stage III NSCLC patients [133].
The predictive effect of initial SUVmax of the primary tumour
for morphological response to chemotherapy has been the topic of
one paper on advanced NSCLC (87 patients) [134]. SUVmax
(dichotomised by the median) was the single significant predictor
in univariate and multivariate analyses, but the patients with high
SUVmax had shorter duration of response and there was no
overall difference in survival between patients with high and low
SUVmax.
The early assessment of the metabolic response after the first
course of chemotherapy has been investigated in two small
studies, suggesting some potential utility for predicting further
survival [135, 136].
Studies of the prediction of morphological response by the
metabolic response have been described in two reports. In the
first one, the metabolic response was shown to have high
predictive value (96%), meaning that, if PET scan does not
show a response, it is very unlikely for one to be documented
by morphological tests [129]. The positive predictive value is,
however, not very good (71%). In the second study, performed
on 89 patients, the correlation between metabolic response
(either visual or based on SUVmax) and morphological response
was poor and the SUVmax measured after chemotherapy did not
predict further survival [73]. We also have to take into account
potential methodological problems due to the lack of standard-
isation.
Recommendation
Metabolic response assessed by PET scan should not be used
for the routine assessment of response to treatment in lung cancer
patients in place of morphological criteria. Level of evidence:
retrospective studies and case series; quality of evidence: 1; grade
of recommendation: Aw.
Statements
The cut-off point of 25% to define response/progression, as
proposed by the EORTC for metabolic response, needs valida-
tion assessment.
Metabolic response requires further investigation with strict
methodology in terms of PET scan examination standardisation,
morphological response assessment, and outcome definition.
QUESTION 8: WHAT IS THE ROLE OF TISSUE
BIOLOGICAL MARKERS FOR THE EVALUATION OF
OVERALL SURVIVAL?
Numerous biomarkers have been tested in lung cancer for
prognostic purposes or for predicting response to chemother-
apy or radiotherapy. Determination of the presence or absence
of a tissue biomarker can be performed by various techniques
(immunohistochemistry, PCR, fluorescence in situ hybridisation
and high-throughput techniques, etc.) that assess cancer biology
at different levels: protein expression, RNA or DNA abnorm-
alities. The question is whether differential expression of tissue
biomarkers during treatment, before and after chemotherapy for
example, could reliably predict treatment efficacy and overall
survival.
Many studies on tissue biomarkers in lung cancer have been
published. They have looked at the prognostic role for survival
of these biological markers, usually obtained at initial diag-
nosis, mainly in NSCLC surgical series. To a lesser extent, their
predictive role for treatment sensitivity was studied. However,
we found only one published study assessing the relationship
between the modifications of tissue biomarkers during therapy
and overall survival [137]. 54 patients with stage III NSCLC
were treated by induction chemotherapy followed by concomi-
tant chemoradiotherapy, and surgery if the tumour became
resectable. There was no difference in the apoptotic indices
before and after neoadjuvant treatment and no statistically
significant impact on survival was observed.
One potential explanation of the lack of studies is related to the
difficulties in easily obtaining adequate tissue samples in lung
cancer patients. This problem is yet more pronounced when a
good response is observed and no surgery is planned.
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Recommendation
Tissue biological markers should not be used for evaluation of
treatment efficacy and are not adequate intermediate criteria for
overall survival in lung cancer patients. Level of evidence: case
series; quality of evidence: 1; grade of recommendation: Aw.
Statements
The role of tissue biological markers in assessing overall survival
in lung cancer needs further investigation with adequate meth-
odology; that is, in terms of positivity definition, and standard-
isation in the evaluation methods and statistical methodology
(multivariate analysis taking into account known prognostic
factors).
QUESTION 9: WHAT IS THE ROLE OF CIRCULATING
MARKERS (MOLECULES OR CELLS) FOR THE
ASSESSMENT OF OVERALL SURVIVAL?
We aimed to determine if modification in the levels of circulating
markers before and after therapeutic procedures in lung cancer
patients can reliably predict overall survival. We selected the
markers as described in the methodology section. We also spe-
cifically searched for biological markers known as potential
prognostic factors in either NSCLC or SCLC: lactate dehydro-
genase, alkaline phosphatases, white cell and neutrophil counts,
platelet count, haemoglobinaemia, natraemia, calcaemia, biliru-
binaemia, cyfra 21-1, carcinoembryonic antigen (CEA), neurone-
specific enolase (NSE), pro-gastrin releasing peptide (pro-GRP),
and other cancer markers such as CA19-9 and CA-125. Publi-
cations were eligible if the correlation between the marker and
overall survival was assessed.
Although the prognostic role for survival of the selected vari-
ables taken at initial diagnosis has been extensively studied, few
studies, summarised in table 8, have been published that assess
the prognostic role on survival of their expression before and
after treatment [138–141, 143, 144, 146–153]. Criteria used by
the authors to define response based on the levels of circula-
ting markers were variable, allowing only indirect comparisons
between studies. It must be pointed out that, of these studies, the
majority was retrospective.
Post-therapy CEA normalisation or significant decrease seems
to be related to better survival in early stage NSCLC treated by
surgery [138, 140–142], in advanced NSCLC with chemother-
apy [139, 143], and after salvage gefitinib in relapsing NSCLC
[144]. Cyfra 21-1 decrease has been reported to be significantly
associated with improved survival in two studies [139, 143]
while no association was observed in a third [146]. For other
factors, it could be suggested from small studies that decreases
TABLE 8 Studies assessing the relationship between modification of circulating markers levels after treatment and survival in
lung cancer
Study P/R Marker Patients n Population Therapy Effect on survival p-value U/M
OKADA et al. [138] R CEA 1000 NSCLC cI Surgery Q for high post-surgical level ,0.0001 M
NISMAN et al. [139] P CEA 45 Advanced NSCLC CT q if Q o35% 0.04 U
SAWABATA et al. [140] R CEA 19 ADC I Surgery Q for high post-surgical level 0.006 U
SAWABATA et al. [141] R CEA 242 NSCLC IA Surgery Q for high post-surgical level ,0.0001 M
SAWABATA et al. [142] R CEA 297 NSCLC cI Surgery Q for high post-surgical level 0.002 M
BRE´CHOT et al. [143] P CEA 116 NSCLC I–IV Various q if Q o50% 0.006 U
CHIU et al. [144] R CEA 89 Relapsing NSCLC Gefitinib q if Q o50% at 4 weeks 0.03 U
SPIRIDONIDIS et al. [145] R CEA, CA19-9,
CA-125
36 NSCLC I–IIIB CT or CT-RT q if Q if decrease 0.0002 U
NISMAN et al. [139] P Cyfra 21-1 45 Advanced NSCLC CT q if Q o35% 0.01 M
HAMZAOUI et al. [146] ? Cyfra 21-1 63 NSCLC/SCLC III–IV CT q if Q o70% 0.44 U
BRE´CHOT et al. [143] P Cyfra 21-1 116 NSCLC I–IV Various q if Q o50% 0.0001 M
SUNAGA et al. [147] R Pro-GRP 29 SCLC I–IV CT q if Q o50% 0.001 M
OKUSAKA et al. [148] R Pro-GRP 18 SCLC in PR CT q if return to normal ,0.05 U
BRE´CHOT et al. [143] P NSE 116 NSCLC I–IV Various q if Q o50% 0.018 U
FIZAZI et al. [149] R NSE 135 SCLC LD/ED CT-RT, CT q if return to normal 0.02 M
BRE´CHOT et al. [143] P CA-125 116 NSCLC I–IV Various q if Q o50% 0.0006 U
CHIU et al. [144] R CA-125 89 Relapsing NSCLC Gefitinib No effect 0.12 U
CHIU et al. [144] R CA19-9 89 Relapsing NSCLC Gefitinib q if Q o25% at 8 weeks ,0.0001 U
GAUTHIER et al. [150] R Anaemia 242 NSCLC IB–II Surgery + CT No effect 0.06 U
LAURIE et al. [151] R Anaemia 652 SCLC LD CT-RT No effect 0.33 U





CHEN et al. [153] P CTC 67 NSCLC I–IIIB CT-RT Persistence of CTC ,0.001 M
YAMASHITA et al. [154] P CTC 103 NSCLC I–IIIA Surgery Persistence of CTC NS M
P: prospective study; R: retrospective study; U: results obtained in univariate analysis; M: results obtained in multivariate analysis; CEA: carcinoembryonic antigen;
NSCLC: nonsmall cell lung cancer; CT: chemotherapy; ADC: adenocarcinoma; CT-RT: chemoradiotherapy; SCLC: small cell lung cancer; pro-GRP: pro-gastrin releasing
peptide; PR: partial remission; NSE: neurone-specific enolase; LD: limited disease; ED: extensive disease; CTC: circulating tumour cells; NS: statistically nonsignificant.
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in the following in terms of blood levels were predictive of
better survival: pro-GRP in SCLC, CA19-9 in relapsing NSCLC,
CA-125 in NSCLC, and NSE in NSCLC and SCLC [143, 144,
147–149]. Anaemia occurring during chemotherapy or chemo-
radiotherapy has not been demonstrated to have prognostic signi-
ficance in two larger studies on NSCLC and SCLC [150, 151].
Lastly, the persistence of circulating tumour cells in blood
was of prognostic significance in locoregional NSCLC treated
by chemoradiotherapy and in relapsing NSCLC treated with
gefitinib [152–154].
Recommendations
1) Some circulating markers (CEA, Cyfra 21-1, pro-GRP and, to a
lesser extent, NSE, CA-125, and CA19-9), used as single criterion
to assess overall survival, could be adequate intermediate
criteria for survival in lung cancer patients. Level of evidence:
retrospective studies; quality of evidence: 2; grade of recom-
mendation: Fw.
2) The persistence of circulating tumour cells in NSCLC may have
a prognostic impact on further survival. Level of evidence: cohort
studies; quality of evidence: 1; grade of recommendation: Fw.
Statement
The suggested role of circulating markers in assessing overall
survival in lung cancer needs further prospective investigation
with adequate methodology (including the cut-off determina-
tion), that is, in terms of statistical methodology (multivariate
analysis taking into account known prognostic factors).
CONCLUSIONS
Overall survival, or healing for curable disease, is the leading
criterion of efficacy of a treatment in lung cancer patients.
Intermediate criteria are potential or adequate surrogates for
survival, despite some limitations: TTP, PFS, objective res-
ponse, local chest control after radiotherapy, mediastinal and
TNM downstaging in locally advanced NSCLC after induction
therapy before surgery, complete resection and pathological
TNM in resected NSCLC, and a few circulating markers (CEA,
Cyfra 21-1, pro-GRP and, to a lesser extent, NSE, CA-125, and
CA19-9). At the present time, some criteria cannot be used for
predicting overall survival in lung cancer (and therefore
certainly not as surrogates for overall survival): conventional
criteria for radiotherapy response assessment of primary lung
tumour, quality of life evolution under treatment, metabolic
response assessment by FDG-PET scan, and tissue biological
markers. The recommendations in this study highlight the need
for well-designed prospective studies in many instances where
intermediate criteria are of possible interest.
POTENTIAL LIMITATIONS AND PROBLEMS
Literature biases
First, we searched for prospective studies and meta-analyses
looking, as the primary objective, at the association between
intermediate criteria and overall survival. This approach was
recently discussed by BUYSE [155] to demonstrate a possible
association between a surrogate and a clinical end-point, requi-
ring data from multiple randomised trials or meta-analyses. In
most instances considered in these guidelines, this literature was
lacking. Secondly, we searched for secondary end-points of
prospective studies and retrospective series. Although we used
multiple keywords for each topic and an extensive literature
search system (Ovid), it is possible that some studies and series in
which some of the selected criteria were actually reported as
secondary end-points were not retrieved. However, the impact of
this literature bias on the conclusions of these guidelines seems
limited as the level of evidence of this type of study is relatively
weak (low or very low grade of evidence according to the
GRADE system). Furthermore, the inclusion of nonrandomised
studies should induce biases in the interpretation of the literature
results for assessing association between criteria like determina-
tion of objective response and survival. Another potential source
of bias is related to the considered languages. We only took into
account reports written in English, French, German and Dutch
languages that were comprehensible by all of the authors. It must
be underlined that most of the results came from clinical trials in
which patients were strictly selected and do not fully represent
the population treated in routine practice.
Validation studies
Although we found some statistical associations between inter-
mediate criteria and survival in meta-analyses and small-sized
randomised studies, validation studies are required before
definite conclusions can be drawn in most instances. These
studies need to be prospectively designed with the primary
objective being the determination of the relationship between the
considered surrogate and the true end-point. They have to
consider the clinical value of the association when the effect of the
intermediate criterion in predicting survival accounts for only a
limited part of the variability of the survival ratio, as we observed
with TTP [40, 41]. The potential surrogate may have a substantial
noise component due to issues in defining the intermediate
criterion or other factors that may affect the clinical outcome.
Therefore, there are some issues concerning the application of
a surrogate in situations other than those in which the surro-
gacy was asserted. These require knowledge about the relevant
biological variables whereby the treatment or the considered
populations may affect the outcome of primary interest.
Grades of recommendations
In order to grade the guidelines, the ELCWP has chosen the
GRADE system. This internationally accepted grading system
for recommendations has previously been used for lung cancer
by the American College of Chest Physicians [156]. GRADE
has certain advantages. It allows grading of recommendations
based on the level of scientific evidence, which is further
modulated by the quality of the literature (table 1). It also allows
integration into the grade of the recommendations of some
subjective variables, such as the balance between desirable and
undesirable effects, and the values and preferences or the costs
(resource allocation), by guideline writers, which may be of
importance in routine practice but cannot always be derived
from the literature.
Impact of supplementary treatment on overall survival
We selected studies assessing a possible relationship between
a surrogate and overall survival. Preceding or subsequent
therapeutics after the investigated treatment can impact on
overall survival and, potentially, on the relationship with the
intermediate criteria. Unfortunately, in light of the currently
available data, it was not possible to avoid this potential bias in
our literature interpretation.
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We found that validation of intermediate criteria as surrogate
end-points in lung cancer has not really been achieved; further-
more, such a validation may be dependent on the treatment
category considered and the population of patients included in
the trial. The development of new therapies leads us to consider
the use of intermediate criteria to assess their effectiveness in
order to achieve possible reductions in sample size, study
duration or cost. A further set of intermediate outcomes based
on data from gene expression or proteomic platforms will be
proposed in the near future. In this context, the identification of
a set of intermediate outcomes may be important, taking into
account the fact that biological pathways could influence the
beneficial or harmful effects of the treatment, influencing the
final outcome.
To convincingly validate these early markers as surrogates, a
strict methodology has to be developed. Some recommenda-
tions have already been proposed by BUYSE and co-workers
[8, 155] on the use of meta-analyses for validation of clinical
surrogates and biomarkers.
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